The Port-a-Cath system (Pharmacia) is totally implantable and consists of a silicone catheter attached to a 2-5 x 1-3 cm stainless steel chamber with a self sealing injection port. Under local or general anaesthesia, and full aseptic conditions, the catheter is introduced surgically into a central vein and the position of the tip is checked radiographically. Through a second incision lower on the chest wall a subcutaneous pocket for the portal is made by blunt dissection. The catheter is tunnelled subcutaneously and connected to the portal, and the wounds are closed.2 Huber needles, which slice through the silicone septum without coring it (fig 1) , are used to inject drugs percutaneously into the portal. Between courses of treatment the needle is removed, leaving intact skin overlying the portal.
Pseudomonas aeruginosa is the major bronchopulmonary pathogen affecting adolescents and adults with cystic fibrosis.' It is not susceptible to any oral antimicrobial agents generally available and is conventionally treated with intravenous chemotherapy. In patients requiring frequent or prolonged treatment, however, thrombophlebitis of peripheral veins may necessitate central venous access. We report the use of an implantable means of venous access suitable for use in selected patients with cystic fibrosis.
Methods
The Port-a-Cath system (Pharmacia) is totally implantable and consists of a silicone catheter attached to a 2-5 x 1-3 cm stainless steel chamber with a self sealing injection port. Under local or general anaesthesia, and full aseptic conditions, the catheter is introduced surgically into a central vein and the position of the tip is checked radiographically. Through a second incision lower on the chest wall a subcutaneous pocket for the portal is made by blunt dissection. The catheter is tunnelled subcutaneously and connected to the portal, and the wounds are closed.2 Huber needles, which slice through the silicone septum without coring it (fig 1) , are used to inject drugs percutaneously into the portal. Between courses of treatment the needle is removed, leaving intact skin overlying the portal.
In the course of eight months the system was implanted in nine patients (eight of them female) with cystic fibrosis; their age range was 13-38 (median 22) years. As percentages of predicted normal3 their median (range) FEV1 was 32% (17-47%) and FVC 30% (26-62%). They were all chronically colonised by Pseudomonas aeruginosa, and had required a median of four (range 2-12) hospital admissions for intravenous antimicrobial chemotherapy within the previous year. Peripheral venous access had become unsatisfactory in all of them, and six had required central venous catheterisation. Three patients had diabetes mellitus.
In view of poor respiratory function Port-a-Cath implantation was performed under local anaesthesia in eight patients, but one patient underwent general anaesthesia at her own request. The cephalic vein was cannulated in three patients, the external jugular in five, and the internal jugular vein in one patient. The position of the portal was carefully chosen preoperatively to ensure that it interfered as little as possible with chest physiotherapy. In patients regularly undertaking parasternal percussion the portal was sited near the anterior axillary line, and in those performing lateral chest percussion the portal was sited medially.
Results
Implantation of the system took one to two and a half hours to perform. Postoperative pain was well controlled by oral analgesia in seven patients. In one patient pain around the portal during physiotherapy required pethidine for the first week. In a second patient persistent pain around the portal was relieved by resiting the portal. In a third patient the catheter migrated in the subclavian vein and required repositioning. No wound infection, septicaemia (see Addendum), venous thrombosis, or catheter occlusion has occurred.
In all of the patients the system has been used for antimicrobial chemotherapy, and in eight patients this has been 
